JP2015536964A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015536964A5 JP2015536964A5 JP2015541167A JP2015541167A JP2015536964A5 JP 2015536964 A5 JP2015536964 A5 JP 2015536964A5 JP 2015541167 A JP2015541167 A JP 2015541167A JP 2015541167 A JP2015541167 A JP 2015541167A JP 2015536964 A5 JP2015536964 A5 JP 2015536964A5
- Authority
- JP
- Japan
- Prior art keywords
- acceptable salt
- combination
- pharmacologically acceptable
- pharmaceutical
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 claims 9
- 101100381978 Mus musculus Braf gene Proteins 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 230000002062 proliferating effect Effects 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 7
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 7
- 239000003112 inhibitor Substances 0.000 claims 7
- 229960005184 panobinostat Drugs 0.000 claims 5
- FWZRWHZDXBDTFK-ZHACJKMWSA-N panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010058314 Dysplasia Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000009905 Neurofibromatoses Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000004931 neurofibromatosis Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261723925P | 2012-11-08 | 2012-11-08 | |
| US61/723,925 | 2012-11-08 | ||
| PCT/EP2013/073452 WO2014072493A1 (en) | 2012-11-08 | 2013-11-08 | Pharmaceutical combination comprising a b-raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015536964A JP2015536964A (ja) | 2015-12-24 |
| JP2015536964A5 true JP2015536964A5 (enExample) | 2016-12-15 |
Family
ID=49552384
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015541167A Pending JP2015536964A (ja) | 2012-11-08 | 2013-11-08 | Ｂ−ｒａｆ阻害剤とヒストン脱アセチル化酵素阻害剤を含む医薬組合せおよび増殖性疾患の治療におけるそれらの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20150283136A1 (enExample) |
| EP (1) | EP2916834A1 (enExample) |
| JP (1) | JP2015536964A (enExample) |
| CN (1) | CN104994850A (enExample) |
| AU (1) | AU2013343425A1 (enExample) |
| BR (1) | BR112015010477A2 (enExample) |
| CA (1) | CA2890663A1 (enExample) |
| HK (1) | HK1214765A1 (enExample) |
| RU (1) | RU2015121367A (enExample) |
| UA (1) | UA115151C2 (enExample) |
| WO (1) | WO2014072493A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR077975A1 (es) | 2009-08-28 | 2011-10-05 | Irm Llc | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina |
| US11007194B2 (en) | 2011-11-11 | 2021-05-18 | Array Biopharma Inc. | Method of treating a proliferative disease |
| WO2013078264A1 (en) | 2011-11-23 | 2013-05-30 | Novartis Ag | Pharmaceutical formulations |
| EP3757130A1 (en) | 2013-09-26 | 2020-12-30 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| CA2935423C (en) | 2014-01-24 | 2023-11-07 | Dana-Farber Cancer Institute, Inc. | Antibody molecules to pd-1 and uses thereof |
| AU2015210750B2 (en) | 2014-01-31 | 2020-08-20 | Children's Medical Center Corporation | Antibody molecules to TIM-3 and uses thereof |
| WO2015138920A1 (en) | 2014-03-14 | 2015-09-17 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
| WO2016040882A1 (en) | 2014-09-13 | 2016-03-17 | Novartis Ag | Combination therapies of egfr inhibitors |
| KR20170066546A (ko) | 2014-10-03 | 2017-06-14 | 노파르티스 아게 | 조합 요법 |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| WO2016061142A1 (en) | 2014-10-14 | 2016-04-21 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
| JO3746B1 (ar) | 2015-03-10 | 2021-01-31 | Aduro Biotech Inc | تركيبات وطرق لتنشيط الإشارات المعتمدة على "منبه أو تحفيز جين انترفيرون" |
| WO2017019664A1 (en) | 2015-07-28 | 2017-02-02 | University Of Iowa Research Foundation | Compositions and methods of treating cancer |
| ES2878188T3 (es) | 2015-07-29 | 2021-11-18 | Novartis Ag | Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3 |
| EP4378957A3 (en) | 2015-07-29 | 2024-08-07 | Novartis AG | Combination therapies comprising antibody molecules to pd-1 |
| WO2017019897A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
| WO2017058007A1 (en) | 2015-10-01 | 2017-04-06 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Histone deacetylase inhibitors for the use in the treatment of drug resistant melanoma |
| KR20250099459A (ko) | 2015-11-03 | 2025-07-01 | 얀센 바이오테크 인코포레이티드 | Pd-1과 특이적으로 결합하는 항체 및 그의 용도 |
| EP3389712B1 (en) | 2015-12-17 | 2024-04-10 | Novartis AG | Antibody molecules to pd-1 and uses thereof |
| US11179484B2 (en) | 2016-06-24 | 2021-11-23 | University Of Iowa Research Foundation | Compositions and methods of treating melanoma |
| EP3507367A4 (en) | 2016-07-05 | 2020-03-25 | Aduro BioTech, Inc. | CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF |
| CN110291089B (zh) | 2017-01-17 | 2022-05-27 | 海帕瑞吉尼克斯股份有限公司 | 用于促进肝再生或者减少或预防肝细胞死亡的蛋白激酶抑制剂 |
| UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
| WO2018237173A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| UY38247A (es) | 2018-05-30 | 2019-12-31 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
| JP2022548881A (ja) | 2019-09-18 | 2022-11-22 | ノバルティス アーゲー | Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法 |
| US11529335B2 (en) | 2020-07-31 | 2022-12-20 | University Of Iowa Research Foundation | Compositions and methods for treating cancer |
| CA3257280A1 (en) | 2022-05-25 | 2023-11-30 | Msd International Gmbh | COMBINATION OF A BRAF INHIBITOR, AN EGFR INHIBITOR AND A PD-1 ANTAGONIST FOR THE TREATMENT OF COLORECTAL CANCER MSI-H/DMMR, WITH BRAF V600E MUTATION |
| WO2025003956A1 (en) | 2023-06-30 | 2025-01-02 | Pfizer Inc. | High drug loading formulations of encorafenib |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| US20080085902A1 (en) * | 2003-09-23 | 2008-04-10 | Guido Bold | Combination Of A Vegf Receptor Inhibitor Or With A Chemotherapeutic Agent |
| TW200804345A (en) | 2005-08-30 | 2008-01-16 | Novartis Ag | Substituted benzimidazoles and methods of preparation |
| AR077975A1 (es) | 2009-08-28 | 2011-10-05 | Irm Llc | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina |
| DK2688572T3 (en) * | 2011-03-21 | 2017-06-12 | Valcuria Ab | PHARMACEUTICAL COMPOSITION WITH AN HDAC INHIBITOR AND A STEROID AND USE THEREOF |
| CA2844407A1 (en) * | 2011-06-14 | 2012-12-20 | Novartis Ag | Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm |
-
2013
- 2013-11-08 RU RU2015121367A patent/RU2015121367A/ru not_active Application Discontinuation
- 2013-11-08 AU AU2013343425A patent/AU2013343425A1/en not_active Abandoned
- 2013-11-08 EP EP13788784.0A patent/EP2916834A1/en not_active Withdrawn
- 2013-11-08 WO PCT/EP2013/073452 patent/WO2014072493A1/en not_active Ceased
- 2013-11-08 CN CN201380063549.9A patent/CN104994850A/zh active Pending
- 2013-11-08 JP JP2015541167A patent/JP2015536964A/ja active Pending
- 2013-11-08 UA UAA201505166A patent/UA115151C2/uk unknown
- 2013-11-08 US US14/441,750 patent/US20150283136A1/en active Granted
- 2013-11-08 HK HK16102742.9A patent/HK1214765A1/zh unknown
- 2013-11-08 BR BR112015010477A patent/BR112015010477A2/pt not_active IP Right Cessation
- 2013-11-08 CA CA2890663A patent/CA2890663A1/en not_active Abandoned